This bill amends the Controlled Drug Act to clarify exceptions to the existing 34-day limit on prescriptions for controlled drugs, specifically for schedules II and III. The bill repeals and reenacts RSA 318-B:9, IV, allowing for certain exceptions where prescriptions can be filled for more than a 34-day supply. Notably, it permits prescriptions for commercially packaged controlled drugs, such as metered sprays and inhalers, to be filled for up to 60 days. Additionally, it allows prescriptions for amphetamines and methylphenidate hydrochloride to be filled for up to 90 days when used for specific medical conditions, and introduces provisions for topically applied and injectable androgens prescribed for chronic low testosterone, allowing for a 92-day supply under certain conditions.

The new legal language includes specific criteria for filling prescriptions for injectable androgens, which must include a prescriber’s statement regarding the treatment of chronic low testosterone and confirmation that the patient has previously filled 12 monthly prescriptions from the same medical practice. The bill aims to enhance patient care by providing more flexibility in medication supply while ensuring that appropriate safeguards are in place. The act is set to take effect 60 days after its passage.